Novo Nordisk Expands its Partnership with Valo Health to Discover and Develop Novel Therapies for Cardiometabolic Diseases
Shots:
- Novo & Valo have expanded their partnership to discover & develop 9 more novel drugs for obesity, T2D & CV diseases, utilizing the former’s expertise in cardiometabolic diseases & Valo’s Opal computational platform plus mutual ability in human data & genetics
- As per the terms, Valo will get upfront, equity & near-term milestones of $190M, milestone payments for 20 drugs now as well as R&D funds & royalties, making it an aggregate of $4.6B
- The original deal of Sep 2023 included the development of 11 programs in exchange for ~$2.7B incl. upfront, R&D funding, milestones & royalties to Valo, leading to the identification of various novel targets
Ref: Novo Nordisk | Image: Novo Nordisk & Valo Health
Related News:- Novo Nordisk’s Awiqli Receives the CHMP’s Positive Opinion for the Treatment of Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
